There was no association of SOCS1 expression with any other chromosome change. Regarding the molecular gene mutations ( Table 1 ), higher SOCS1 expression was closely associated with NPM1 mutation (33 vs 14.4%, P =0.002) and DNMT3A mutation (22.3 vs 10.8%, P =0.029), and showed a trend to be associated with FLT3 /ITD (30.4 vs 19.8%, P =0.089), but was inversely correlated with CEBPA double mutation (1.8 vs 14.4%, P =0.001).
Functional outcomes at discharge showed a trend toward better recovery in the FD group than the SAC group (mRS 1.9 vs. 2.9, p = 0.089).
Non-CKD patients showed a trend towards numerically higher aldosterone receptor antagonist therapy than CKD patients (31% vs. 13%, p = 0.089).
Moreover, Ureaplasma -positive infants had higher levels of MMP-8 ( p = 0.024) and ICAM-1 ( p = 0.041) and showed a trend toward decreased levels of IL12p40 in cord blood ( p = 0.089).
Age was not a significant predictor (OR = 0.98 per year, p = 0.612), and income ≥ 10,001 SAR showed a trend toward increased access (OR = 1.28, p = 0.089) but did not reach conventional significance.
Kaplan–Meier analysis showed a trend toward worse disease-specific survival (log-rank p = 0.089).
The smaller dataset showed a trend of a correlation between F-actin and CADM1 (P = 0.089, Fig.
The Gal-8 expression in the nucleus correlated negatively with the tumor grading and showed a trend towards a lower IRS in higher tumor grading ( p = 0.089).
Also, the PWSV showed a trend toward being decreased in the WD group ( p = 0.089).
Among patients who had a KIT exon 11 mutation (n=40), the 5-year group still showed a trend toward a better RFS (p=0.089; 4-year RFS, 83.3% vs. 61.5%, respectively) ( S3 Fig. ).
The same locus showed increased methylation in glial cells (exp( β ) = 0.041, p value ~ 0.004) in the validation cohort, involving 29 depressed patients and 29 controls, and showed a trend for association with suicide ( n = 40, p value ~ 0.089) and trend for association with depression treatment ( n = 377, p value ~ 0.075).
Controlling for sex, those with PEMCS showed a trend towards higher odds of PLEs in adolescence ( P = 0.089), and strong evidence for more inattention and hyperactivity in adolescence ( P < 0.001) and more other externalizing behaviors ( P < 0.001).
Tumors with low TSPO expression originating from the oral cavity ( Figure 2A ) showed a trend (p = 0.089) towards worse OS.
Additionally, the presence of tumor margin protrusions during the portal venous phase showed a trend toward statistical significance (OR = 5.94, P = 0.089).
26 months, p = 0.009) resulted in significant differences (Figure 2 ), while pHH3 index ≤0.8 versus >0.8 showed a trend (p = 0.089).
For the night before baseline cognitive testing, the MCI reversion group showed a trend toward shorter TST compared to the maintenance group (6.12 ± 1.33 vs. 6.75 ± 1.20 hours, p = 0.089).
As predicted, PQ/PTS rats showed a trend toward significance, F (2, 33) = 2.60, p = 0.089, η 2 = 0.136.
Low birth weight (<2,500 g) showed a trend toward association that did not reach statistical significance (adjusted OR = 2.45; 95% CI: 0.87-6.91; P = 0.089) (Table 1 ).
The biomarker × treatment interaction for ImPrint was significant in the training IO arm versus control ( P = .045) and showed a trend in five IO arms combined versus control ( P = .089).
While pre-procedural INR > 1.5 showed a trend towards increased risk (OR 2.78), it did not reach statistical significance in this model ( p = 0.089).
Multivariable Cox regression showed a trend toward shorter survival time ( P = .089) in the antibiotic group.
Mortality at day 7 showed a trend to better outcomes with steroids (16.5% vs 23.6%, p = 0.089) but this had largely reversed by day 14 (27.3% vs 31.7%, p = 0.29).
5 B) and showed a trend toward shorter disease-free survival (HR = 1.3, log-rank P = 0.089; Fig. 5 C).
Between-group variation showed a trend of alteration between ZEN group and control group (R = 0.740741, P = 0.089) ( Figure 3 G).
In the ZOL group, the incidence of new-onset fractures showed a trend of negative correlation with the percentage change in serum β-CTX level at month 12 (r = −0.135, p = 0.089).